159 related articles for article (PubMed ID: 31129615)
1. Practical application of non-contact alternating current electric field mixing for reagent-saving in situ hybridisation of HER2.
Kurihara N; Imai K; Nanjo H; Nakamura R; Wakamatsu Y; Akagami K; Terata K; Wakita A; Sato Y; Motoyama S; Akagami Y; Minamiya Y
J Clin Pathol; 2019 Sep; 72(9):603-608. PubMed ID: 31129615
[TBL] [Abstract][Full Text] [Related]
2. Reagent-saving immunohistochemistry for HER2 using non-contact alternating current electric field mixing.
Hoshino I; Imai K; Nanjo H; Nakamura R; Saito Y; Fujishima S; Saito H; Terata K; Wakita A; Sato Y; Motoyama S; Akagami Y; Minamiya Y
J Clin Pathol; 2019 Jan; 72(1):25-30. PubMed ID: 30228214
[TBL] [Abstract][Full Text] [Related]
3. Novel method for rapid in-situ hybridization of HER2 using non-contact alternating-current electric-field mixing.
Saito Y; Imai K; Nakamura R; Nanjo H; Terata K; Konno H; Akagami Y; Minamiya Y
Sci Rep; 2016 Jul; 6():30034. PubMed ID: 27443187
[TBL] [Abstract][Full Text] [Related]
4. Rapid HER2 cytologic fluorescence in situ hybridization for breast cancer using noncontact alternating current electric field mixing.
Watanabe SN; Imai K; Nanjo H; Wakamatsu Y; Kimura Y; Katayose Y; Kamata S; Terata K; Takahashi E; Ibonai A; Yamaguchi A; Konno H; Yatsuyanagi M; Kudo C; Takashima S; Akagami Y; Nakamura R; Sato Y; Motoyama S; Nomura K; Minamiya Y
Cancer Med; 2021 Jan; 10(2):586-594. PubMed ID: 33280268
[TBL] [Abstract][Full Text] [Related]
5. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.
Carbone A; Botti G; Gloghini A; Simone G; Truini M; Curcio MP; Gasparini P; Mangia A; Perin T; Salvi S; Testi A; Verderio P
J Mol Diagn; 2008 Nov; 10(6):527-36. PubMed ID: 18832456
[TBL] [Abstract][Full Text] [Related]
6. Updated UK Recommendations for HER2 assessment in breast cancer.
Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
[TBL] [Abstract][Full Text] [Related]
7. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
8. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
9. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer.
Mansfield AS; Sukov WR; Eckel-Passow JE; Sakai Y; Walsh FJ; Lonzo M; Wiktor AE; Dogan A; Jenkins RB
Am J Clin Pathol; 2013 Feb; 139(2):144-50. PubMed ID: 23355198
[TBL] [Abstract][Full Text] [Related]
10. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
[TBL] [Abstract][Full Text] [Related]
11. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
12. HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays.
Yau TK; Sze H; Soong IS; Hioe F; Khoo US; Lee AW
Hong Kong Med J; 2008 Apr; 14(2):130-5. PubMed ID: 18382020
[TBL] [Abstract][Full Text] [Related]
13. Improved concordance of challenging human epidermal growth factor receptor 2 dual in-situ hybridisation cases with the use of a digital image analysis algorithm in breast cancer.
Gough M; Liu C; Srinivasan B; Wilkinson L; Dunk L; Yang Y; Schreiber V; Tuffaha H; Kryza T; Hooper JD; Lakhani SR; Snell CE
Histopathology; 2023 Oct; 83(4):647-656. PubMed ID: 37366040
[TBL] [Abstract][Full Text] [Related]
14. Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections.
Nishimura R; Okamoto N; Satou M; Kojima K; Tanaka S; Yamashita N
Breast Cancer; 2016 Nov; 23(6):917-921. PubMed ID: 26746842
[TBL] [Abstract][Full Text] [Related]
15. Comparison of fluorescence in-situ hybridisation with dual-colour in-situ hybridisation for assessment of HER2 gene amplification of breast cancer in Hong Kong.
Tang SM; Soong IS; Luk MY; Suen DT; Hioe F; Man EP; Tsun OK; Khoo US
Hong Kong Med J; 2016 Apr; 22(2):144-51. PubMed ID: 26823385
[TBL] [Abstract][Full Text] [Related]
16. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
17. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation.
Koopman T; van der Vegt B; Dijkstra M; Bart J; Duiker E; Wisman GBA; de Bock GH; Hollema H
Histopathology; 2018 Nov; 73(5):852-863. PubMed ID: 29989198
[TBL] [Abstract][Full Text] [Related]
18. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study.
Bilous M; Ades C; Armes J; Bishop J; Brown R; Cooke B; Cummings M; Farshid G; Field A; Morey A; McKenzie P; Raymond W; Robbins P; Tan L
Breast; 2003 Apr; 12(2):92-8. PubMed ID: 14659337
[TBL] [Abstract][Full Text] [Related]
19. Determination of HER2 gene amplification in breast cancer using dual-color silver enhanced in situ hybridization (dc- SISH) and comparison with fluorescence ISH (FISH).
Unal B; Karaveli FS; Pestereli HE; Erdogan G
Asian Pac J Cancer Prev; 2013; 14(10):6131-4. PubMed ID: 24289638
[TBL] [Abstract][Full Text] [Related]
20. Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer.
Horii R; Matsuura M; Iwase T; Ito Y; Akiyama F
Breast Cancer; 2014 Sep; 21(5):598-604. PubMed ID: 23307494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
